Orludodstat
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 29, 2018 (NCT03404726)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Dihydroorotate dehydrogenaseINHIBITOR
DHODH inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05061251 | Early Phase 1 (Phase 1) | Dec 1, 2021 | Bayer, The University of Texas, Dallas |
| NCT03404726 | Phase 1 | Mar 29, 2018 | Bayer |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 2 | 1 | 1 | 2018 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1